Target Gene/Pathway💬 Info on mouse-over

No.	KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related	KEGG GENES	KEGG DRUG	DrugBank	Disease ID
1	Adipocytokine signaling pathway 💬	[1] JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
2	AGE-RAGE signaling pathway in diabetic complications 💬	[1] JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
3	Chemokine signaling pathway 💬	[1] JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
4	Cholinergic synapse 💬	[1] JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
5	Coronavirus disease - COVID-19 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
6	EGFR tyrosine kinase inhibitor resistance 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
7	Epstein-Barr virus infection 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
8	Growth hormone synthesis, secretion and action 💬	[1] JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
9	Hepatitis B 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
10	Hepatitis C 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
11	Herpes simplex virus 1 infection 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
12	Human cytomegalovirus infection 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
13	Human papillomavirus infection 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
14	Human T-cell leukemia virus 1 infection 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
15	Influenza A 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
16	JAK-STAT signaling pathway 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
17	Kaposi sarcoma-associated herpesvirus infection 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
18	Leishmaniasis 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
19	Measles 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
20	Necroptosis 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
21	NOD-like receptor signaling pathway 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
22	Osteoclast differentiation 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
23	Pancreatic cancer 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
24	Pathways in cancer 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
25	PD-L1 expression and PD-1 checkpoint pathway in cancer 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
26	PI3K-Akt signaling pathway 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
27	Prolactin signaling pathway 💬	[1] JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
28	Signaling pathways regulating pluripotency of stem cells 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
29	Th1 and Th2 cell differentiation 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
30	Th17 cell differentiation 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
31	Toxoplasmosis 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
32	Tuberculosis 💬	[2] JAK1, JAK2 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
33	Viral carcinogenesis 💬	[1] JAK1 💬	D10308 💬	Baricitinib	[9] 41, 46, 49, 50, 93, 107, 265, 268, 325 💬

Back to top